GCG and metabolic dysfunction-associated steatohepatitis: According to the American Association for the Study of Liver Diseases 2018 practice guidance [40], however, it is premature to consider GLP-1-RA to specifically treat NASH and NAFLD patients without T2D because of insufficient evidence.